If You Can't Make Your Drug a Blockbuster, Sue Your Competitor
Amarin sues AstraZeneca over its fish oil pill Epanova. If the companies can't reach sales close to GlaxoSmithKline's Lovaza, it will be for naught.
What This FDA Decision Means for Amarin Investors
Investors barely twitched when Amarin Corp. (NASDAQ: AMRN) announced earlier that the FDA had denied new chemical entity status for Vascepa, its fish oil-based therapy for high triglycerides—and for good reason. Amarin's stock hit bottom hard in October when the EMDAC vote went against the drug, and the biotech's flatlined stock is unlikely to do anything interesting until the outcome of its legal wrangling with the FDA is determined.
Can Amarin Corporation PLC Stop Burning Cash?
Amarin has to diferentiate Vasecepa from GlaxoSmithKline's and AbbVie's drugs or cuts costs massively.
Will Offshore Tax Havens Face More Scrutiny in 2014?
Standard and Poors says offshore tax havens will face tighter regulation in 2014. Could stocks be affected?
Two Years Less Exclusivity Is the Least of Amarin's Issues
Amarin's patents holding up in court and being able to compete with GlaxoSmithKline's Lovaza for patients are much bigger deals.
Monday’s Winners and Losers: Celsion Corporation, Celladon Corp, and Amarin Corporation plc
Celsion and Celladon Corp scored wins in the health-care space today, while Amarin gets some bad news.
Amarin Given 3-Year Exclusivity for Vascepa
Amarin is granted exclusivity from the FDA, but was hoping for a longer term.
3 Biotech Stocks to Avoid: Amarin, Dendreon, and Prosensa
Amarin, Dendreon, and Prosensa are three biotech stocks which should be avoided at all costs. Here’s why.
Amarin Corporation Plc's Rocky Road
A video discussing Amarin's issues, compounded by competition from GlaxoSmithKline and issues over trails run on drugs from Merck and AbbVie.
5 of Last Week's Biggest Losers
These five stocks posted double-digit percentage declines this past week.